Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 301

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 301
---
 proceeds.

In September 2021, we entered
into several convertible loan agreements entered into in September 2021, or the 2021 CLAs, pursuant to which we obtained a convertible
loan in the aggregate amount of $835,000. In connection with the 2021 CLAs, the lenders were granted warrants to purchase shares of the
Company of the same class of the conversion securities. Effective as of March 11, 2024, the 2021 CLAs were converted into 35,354 Ordinary
Shares and the warrants granted thereunder expired in full in December 2023.

Between October 2024 and November
2024, we entered into Bridge Loans, pursuant to which we obtained a bridge loan from the lenders thereto including certain related parties.
In October 2024, we amended the Bridge Loans pursuant to which the Bridge Loans have been extended until August 31, 2025 and shall bear
interest at 8% per annum until maturity commencing as of September 1, 2024. Furthermore, upon the occurrence of a Qualifying IPO, the
Bridge Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to two times their respective loan amount
in addition to a risk premium based on a price per share equal to 75% of the lowest price per share of the Ordinary Shares during the
first five trading days following the consummation of such initial public offering. As of January 15, 2025, the Company received $250,000
under such Bridge Loans.

Between December 2023 and
January 2024, we entered into the 2024 Loan Agreements pursuant to which we obtained a loan in the aggregate amount of $150,000 from the
lenders thereto including certain related parties. In October 2024, we amended the 2024 Loan Agreements pursuant to which the 2024 Loan
Agreements have been extended until August 31, 2025 and shall bear interest at 8% per annum until maturity commencing as of September
1, 2024. Furthermore, upon the occurrence of a Qualifying IPO, the 2024 Loan Agreements lenders, shall be granted warrants to purchase
such number of Ordinary Shares equal to two times their respective loan amount in addition to a risk premium based on a price per share
equal to 75% of the lowest price per share of the Ordinary Shares during the first five trading days following the consummation of such
initial public